New Pre-Symptomatic Screening Test for Ovarian Cancer Coming

There Is a New Pre-Symptomatic Screening Test for Ovarian Cancer Coming
From Arrayit Corporation, and It Will Be Available Soon

Noninvasive Test Will Provide Hope for 90% of Women Diagnosed With This Silent Killer

SUNNYVALE, CA–(Marketwire – 01/07/10) – On December 9th, 2009, Arrayit Corporation (OTCBB: ARYC) , a leading manufacturer of products and services for disease prevention, treatment and cure,
announced a breakthrough in ovarian cancer screening utilizing a microarray-based diagnostic
test that will detect whether a patient is pre-symptomatic for this silent killer.

In a report by NBC`s Dr. Robert Bezell on Tuesday, January 5th, it was reported that although
research continues, there is no effective screening test currently available to detect the
pre-symptomatic presence of ovarian cancer. The report missed the mark, which indicates that press
information distributed by Arrayit on December 9th, somehow fell through the cracks. The fact
is, Arrayit`s advanced screening test, OvaDx(TM), will be available very soon.

Researchers at a major cancer research institute have worked for six years to identify more than 100 biomarkers
unique to ovarian cancer. The proteomic markers were finally identified using a novel and
patented microarray platform created by Arrayit. A noninvasive screening test can be
performed via a simple blood test that can be conducted during annual physical exams. The test will
soon be submitted to the FDA for approval, and since it is an in vitro diagnostic
multivariate index assay, prompt approval is anticipated.

According to the American Cancer Society, more than 21,500 women will be diagnosed with Ovarian Cancer this year, and
14,000 will die. Up until now, screening tests could only detect the `Silent Killer` when the
disease is symptomatic, meaning the disease has progressed to stage 3 or 4. Unfortunately at
this late stage of detection the cancer most certainly has metastasized and spread beyond the ovary,
which proves fatal for 75% of women diagnosed.

Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the
female reproductive system. Clinicians state that the primary reasons for such a high
fatality rate are that there are no discernable early symptoms, and there has not been an effective
early detection test available. The American Cancer Society estimates that 90% of woman diagnosed
with ovarian cancer could survive with early detection. Currently only 20% of women diagnosed are
in the early stages.

The early detection of ovarian cancer holds tremendous potential to profoundly impact the quality of life of
ovarian cancer victims and shift costs from treatment to detection ensuring survivability for a
larger population. Upon FDA approval, OvaDx(TM) will be marketed and sold by Arrayit
Corporation`s subsidiary, Arrayit Diagnostics (Ovarian), Inc., in Houston, Texas under a licensing agreement.